Table 3 Demographic data, the patient characteristics and ECMO data of 6 included studies with MERS outbreak (2012–2015)
From: ECMO use in COVID-19: lessons from past respiratory virus outbreaks—a narrative review
First author | Country | Study design | Study population | ECMO pts./total pts. | Age of ECMO pts. (years) | PaO2/FIO2a (mmHg) | MV durationa (days) | ECMO duration (days) | Discharged aliveb, n (%) |
|---|---|---|---|---|---|---|---|---|---|
Choi WS [10] | South Korea | Retrospective/multicentre | Ward and ICU | 13/186 | NA | NA | NA | NA | 8 (61.5%) |
Rhee JY [11] | Case review/single centre | Ward and ICU | 1/5 | 35 | 53 | 0 (4 h) | 6 | 0 | |
Al-Dorzi HM [12] | Saudi Arabia | Prospective/single centre | HCW in ICU | 1/8 | NA | NA | NA | 15 | 0 |
Arabi YM [13] | Retrospective/multicentre | ICU | 19/330 | NA | NA | NA | NA | 6 (31.6%) | |
Alshahrani MS [14] | Retrospective/multicentre | ICU | 17/35 | 45.5 (28.5–58.5) | NA | NA | NA | 6 (35.3%) | |
Shalhoub S [15] | Retrospective/multicentre | HCW in ward and ICU | 9/32 | NA | NA | NA | NA | 4 (44.4%) |